SCHEMBL7566762

SCHEMBL7566762

CC(C)c1c(C(=O)N/N=C\c2ccco2)[nH]c2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.61
NPC1 O15118 3/20 0.53
RAB9A P51151 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
KMT2A Q03164 4/20 0.51
MAPT P10636 3/20 0.50
POLB P06746 3/20 0.50
TDP1 Q9NUW8 2/20 0.50
AHR P35869 1/20 0.50
CTDSP1 Q9GZU7 1/20 0.50
ALDH1A1 P00352 1/20 0.48
GAA P10253 3/20 0.48
CYP1A2 P05177 2/20 0.48
KDM4E B2RXH2 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
PKM P14618 1/20 0.47
NPSR1 Q6W5P4 1/20 0.46
HPGD P15428 1/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7536257 1.00 MAPK1 (0.61) MAPK1NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL7559838 0.85 MAPK1 (0.64) MAPK1NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL7559841 0.85 MAPK1 (0.64) MAPK1NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL7562436 0.84 ALDH1A1 (0.61) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL7562433 0.84 ALDH1A1 (0.61) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL7559725 0.83 SMN1; SMN2 (0.57) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL7559728 0.83 SMN1; SMN2 (0.57) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL7560903 0.81 MAPK1 (0.62) MAPK1NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL7530911 0.81 MAPK1 (0.62) MAPK1NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL7528196 0.81 TDP1 (0.46) MAPK1RAB9ASMN1; SMN2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MAPK1 2111/4885NPC1 3749/4885RAB9A 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.